Cargando…
Case report: Moderate therapeutic response to Bevacizumab in late-onset Labrune syndrome
Labrune syndrome (LS) is caused by SNORD118 gene mutations with a particular neuroimaging of white matter disease, intracranial calcification, and cysts. There was no effective treatment until now. An 18-year-old man with infancy-onset LS was first treated with vascular endothelial growth factor (VE...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552879/ https://www.ncbi.nlm.nih.gov/pubmed/36237624 http://dx.doi.org/10.3389/fneur.2022.968403 |